StockNews.AI
ZLAB
StockNews.AI
203 days

Zai Lab to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Recent Corporate Updates on February 27, 2025

1. Zai Lab will report Q4 and full year 2024 results on February 27, 2025. 2. A conference call will follow the financial results announcement. 3. Zai Lab focuses on innovative biopharmaceuticals addressing significant medical needs.

Earnings
+0.78%Current Return
VS
+0.56%S&P 500
$26.8401/28 07:56 AM EDTEvent Start
$27.0501/29 02:48 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

The financial results will provide insights but are expected to be consistent with trends.

How important is it?

Earnings announcements significantly impact stock performance, but recent trends suggest stability.

Why Short Term?

The upcoming financial results may influence pricing in the immediate period following the announcement.

Related Companies

ZLAB9688.HK
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT). Conference Call and Webcast Information Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call. Details are as follows: Registration Link: https://register.vevent.com/register/BI628d3dd054cb4c45b3d01b61fa5779b1 All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering. A replay will be available shortly after the call and can be accessed by visiting the Company's website. About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide. For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.X.com/ZaiLab_Global.

Related News